5 replies to this topic

[nootropi]

Source for the screen shot I posted

Attached Files

•  befotiamine.JPG   183.8KB   11 downloads

[nootropi]

Here is the abstract:

Attached Files

•  benfotim2.JPG   130.15KB   3 downloads

[stellar]

Nootropi,

Benfotiamine looks good, it inhibits nuclear factor kappa b (nfkb).
"Nuclear factor kB (NF-kB) is a nuclear transcription factor that regulates expression of a large number of genes that are critical for the regulation of apoptosis, viral replication, tumorigenesis, inflammation, and various autoimmune diseases."

By inducing NFKB you open yourself up to the release of inflammatory cytokines ie tumor necrosis factor-alpha (tnf-a). Inhibiting it is a good thing. Other NfKb inhibitors include N-Acetyl-Cystine, Curcumin, Ginko Biloba, Alpha Lipoic Acid, and so on.

1: Nat Med. 2003 Mar;9(3):294-9. Epub 2003 Feb 18. Related Articles, Links
Click here to read
Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy.

Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M.

Medical Clinic V, School of Clinical Medicine, Mannheim, Germany.

Three of the major biochemical pathways implicated in the pathogenesis of hyperglycemia induced vascular damage (the hexosamine pathway, the advanced glycation end product (AGE) formation pathway and the diacylglycerol (DAG)-protein kinase C (PKC) pathway) are activated by increased availability of the glycolytic metabolites glyceraldehyde-3-phosphate and fructose-6-phosphate. We have discovered that the lipid-soluble thiamine derivative benfotiamine can inhibit these three pathways, as well as hyperglycemia-associated NF-kappaB activation, by activating the pentose phosphate pathway enzyme transketolase, which converts glyceraldehyde-3-phosphate and fructose-6-phosphate into pentose-5-phosphates and other sugars. **In retinas of diabetic animals, benfotiamine treatment inhibited these three pathways and NF-kappaB activation*** by activating transketolase, and also prevented experimental diabetic retinopathy. The ability of benfotiamine to inhibit three major pathways simultaneously might be clinically useful in preventing the development and progression of diabetic complications.

PMID: 12592403 [PubMed - indexed for MEDLINE]

[scottl]

I'm a bit pressed for time. Benfotiamine is definitely good stuff. I'm not sure about 600 mg/day. That study was in type I diabetics. Paul Wakfur's (morelife guy) regimen includes 360/day.

I'd be curious if AOR support has any thoughts on what a preventative dose would be for a healthy adult.

[AORsupport]

This study shows that 600 mg/d benfotiamine reduces CML in type I diabetics' red blood cells within a one month time frame; it does not show that this is the most effective dose for anything in particular, let alone for long-term use and actual health benefits.

The clinical trials clearly show that benfotiamine is effective against diabetic neuropathy at 300-400 mg/day; several studies show that it works if bumped down to 150 mg/day after the first month. It may be that there are yet greater benefits at 600 mg/day, but we have no evidence to specifically support this idea, and it seems likely to be a needlessly high dose for a healthy life extensionist.

Here is a detailed article on benfotiamine, complete with references. AOR was the first company in North America to make benfotiamine supplements available.

To your health!

AOR

[nootropi]

This study shows that 600 mg/d benfotiamine reduces CML in type I diabetics' red blood cells within a one month time frame; it does not show that this is the most effective dose for anything in particular, let alone for long-term use and actual health benefits.

This means essentially that a higher dose is more effective at reducing AGE. So you are in fact wrong.

The clinical trials clearly show that benfotiamine is effective against diabetic neuropathy at 300-400 mg/day; several studies show that it works if bumped down to 150 mg/day after the first month. It may be that there are yet greater benefits at 600 mg/day, but we have no evidence to specifically support this idea, and it seems likely to be a needlessly high dose for a healthy life extensionist.

Once again, your reasoning is obtuse. The reason befotiamine is ingested is specifically to reduce AGEs. Less AGE, less aging; it is that simple.

Here is a detailed article on benfotiamine, complete with references.

AOR was the first company in North America to make benfotiamine supplements available.

Wow, thanks for the article. It is helpful; however, it is totally irrelevant when your company made a supplement available.